LifeMD Expands Pharmacy Services with Non-Sterile Compounding to Deliver Personalized, Cost-Efficient Therapies at Scale
LifeMD (Nasdaq: LFMD) has expanded its affiliated pharmacy services to include non-sterile compounding capabilities for oral and topical medications. This enhancement follows the August 2024 launch of their commercial pharmacy, which can process up to 5,000 prescriptions daily.
The expanded facility will enable LifeMD to formulate customized medications, including allergen-free and combination products not commercially available. Operating under FDA's 503A designation, the pharmacy is currently licensed in 13 states and aims to secure licenses across all 50 states within 12 months.
This strategic expansion supports LifeMD's core service areas in men's and women's health and dermatology while reducing third-party provider dependence and improving operational efficiency.
LifeMD (Nasdaq: LFMD) ha ampliato i servizi di farmacia affiliata includendo capacità di preparazioni non sterili per medicinali orali e topici. Questo aggiornamento segue il lancio della loro farmacia commerciale nell'agosto 2024, che può elaborare fino a 5.000 ricette al giorno. Il nuovo stabilimento permetterà LifeMD di formulare medicinali personalizzati, inclusi prodotti senza allergeni e combinazioni non disponibili in commercio. Operando secondo la designazione FDA 503A, la farmacia è attualmente autorizzata in 13 stati e punta ad ottenere licenze in tutti i 50 stati entro 12 mesi. Questa espansione strategica sostiene le aree principali di servizio di LifeMD in salute maschile e femminile e dermatologia, riducendo la dipendenza da fornitori terzi e migliorando l'efficienza operativa.
LifeMD (Nasdaq: LFMD) ha ampliado los servicios de su farmacia afiliada para incluir capacidades de preparación no estéril para medicamentos orales y tópicos. Esta mejora sigue al lanzamiento, en agosto de 2024, de su farmacia comercial, que puede procesar hasta 5.000 recetas diarias. La nueva instalación permitirá a LifeMD formular medicamentos personalizados, incluidos productos sin alérgenos y combinaciones no disponibles comercialmente. Bajo la designación 503A de la FDA, la farmacia está actualmente licenciada en 13 estados y apunta a obtener licencias en los 50 estados en un plazo de 12 meses. Esta expansión estratégica respalda las áreas centrales de servicio de LifeMD en salud masculina y femenina y dermatología, al tiempo que reduce la dependencia de proveedores externos y mejora la eficiencia operativa.
LifeMD (Nasdaq: LFMD)는 자매 약국의 서비스를 확장하여 비멸균 조제 능력을 경구 및 외용 약물에 포함했습니다. 이 확장은 2024년 8월 상용 약국 출시 이후의 조치로, 하루 최대 5,000건의 처방을 처리할 수 있습니다. 확장된 시설은 알레르겐 프리 및 시판되지 않는 조합 약물을 포함한 맞춤 의약품 제제를 가능하게 할 것입니다. FDA의 503A 지정 하에 이 약국은 현재 13개 주에서 면허를 보유하고 있으며 12개월 내에 50개 주 전체의 면허 확보를 목표로 하고 있습니다. 이 전략적 확장은 남성 건강, 여성 건강 및 피부과의 핵심 서비스 영역을 지원하면서 제3자 공급자의 의존도를 줄이고 운영 효율을 개선합니다.
LifeMD (Nasdaq: LFMD) a étendu les services de sa pharmacie affiliée pour inclure des capacités de préparation non stérile pour des médicaments oraux et topiques. Cette amélioration fait suite au lancement en août 2024 de leur pharmacie commerciale, qui peut traiter jusqu'à 5 000 ordonnances par jour. L'installation élargie permettra à LifeMD de former des médicaments personnalisés, y compris des produits sans allergènes et des associations non disponibles dans le commerce. Opérant sous la désignation 503A de la FDA, la pharmacie est actuellement licenciée dans 13 États et vise à obtenir des licences dans les 50 États dans les 12 mois. Cette expansion stratégique soutient les domaines clés des services de LifeMD en santé masculine et féminine et en dermatologie, tout en réduisant la dépendance vis-à-vis des prestataires tiers et en améliorant l'efficacité opérationnelle.
LifeMD (Nasdaq: LFMD) hat die Dienste seiner angeschlossenen Apotheke erweitert und nicht steril herzustellende Zubereitungen für orale und topische Medikamente eingeführt. Diese Aufrüstung folgt dem im August 2024 gestarteten kommerziellen Apothekenbetrieb, der bis zu 5.000 Verschreibungen pro Tag verarbeiten kann. Die erweiterte Einrichtung ermöglicht LifeMD, maßgeschneiderte Medikamente herzustellen, einschließlich allergenfreier Produkte und Kombinationen, die kommerziell nicht erhältlich sind. Unter der FDA-503A-Bezeichnung ist die Apotheke derzeit in 13 Bundesstaaten lizenziert und zielt darauf ab, innerhalb von 12 Monaten Lizenzen in allen 50 Bundesstaaten zu sichern. Diese strategische Expansion unterstützt LifeMDs Kernbereiche in Männergesundheit, Frauengesundheit und Dermatologie, reduziert die Abhängigkeit von Drittanbietern und verbessert die operative Effizienz.
LifeMD (Nasdaq: LFMD) وسّعت خدمات صيدلتها التابعة لتشمل قدرات تركيب غير معقّمة للأدوية الفموية والموضعية. تأتي هذه الترقية بعد إطلاق صيدليتها التجارية في أغسطس 2024، والتي يمكنها معالجة حتى 5,000 وصفة يومياً. ستتيح المنشأة الموسّعة لـ LifeMD صياغة أدوية مخصصة، بما في ذلك المنتجات الخالية من مسببات الحساسية والتركيبات غير المتاحة تجارياً. تعمل الصيدلية تحت تصنيف FDA 503A، وهي حالياً مرخّصة في 13 ولاية وتسعى للحصول على تراخيص في جميع الولايات الـ50 خلال 12 شهراً. تعزز هذه التوسعة الاستراتيجية مجالات خدمة LifeMD الأساسية في صحة الرجال والنساء والجلدية، مع تقليل الاعتماد على مقدمي الخدمات من الطرف الثالث وتحسين الكفاءة التشغيلية.
LifeMD（纳斯达克：LFMD） 已将其附属药房服务扩展为提供非无菌配制能力，用于口服和外用药物。这一升级是在2024年8月推出商业药房之后，每日可处理多达5,000份处方的药房。这一扩建将使 LifeMD 能配制定制药物，包括无过敏原和市场上尚无的组合药物。该药房在 FDA 的 503A 指定下，目前已在13个州获得执照，计划在12个月内在所有50个州取得许可。此次战略扩张支持 LifeMD 在男性健康、女性健康和皮肤科等核心服务领域，同时降低对第三方供应商的依赖并提升运营效率。
- Enhanced ability to provide personalized medications through non-sterile compounding
- Capacity to process up to 5,000 prescriptions per day
- Reduced dependence on third-party providers, potentially improving margins
- Expected expansion from 13 to 50 state licenses within 12 months
- None.
Insights
LifeMD's pharmacy expansion adds non-sterile compounding capabilities, strengthening vertical integration while driving margin improvements and operational efficiencies.
LifeMD's strategic expansion into non-sterile compounding represents a significant vertical integration milestone for their healthcare delivery model. The company launched its commercial pharmacy just last month with impressive capacity to process up to 5,000 prescriptions daily, and is now enhancing those capabilities with custom medication formulation services.
This move addresses several business imperatives simultaneously. By bringing compounding in-house, LifeMD reduces dependency on third-party pharmacies, which should translate to improved margins and greater quality control. The 503A designation allows them to create personalized medications tailored to specific patient needs, particularly valuable in their core service areas of men's and women's health and dermatology where customized formulations are often beneficial.
The company's pharmacy licensing timeline is aggressive but achievable, currently operating in 13 states with plans to expand to all 50 within 12 months. This rapid scaling indicates confidence in their operational infrastructure and regulatory compliance capabilities. The virtual care model paired with in-house pharmacy services creates a more seamless patient experience—a key differentiator in the competitive telehealth market.
From an operational perspective, bringing compounding capabilities in-house should reduce fulfillment times and enhance supply chain resilience. This integration aligns with broader healthcare trends toward personalized medicine and patient-centric care models, positioning LifeMD to capitalize on the growing demand for customized therapeutic approaches in virtual care delivery.
Enhanced Affiliated Pharmacy Capabilities Support Specialized Therapies, Seamless Patient Experience, and Margin Expansion
NEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced the expansion of its state-of-the-art affiliated pharmacy to include advanced non-sterile compounding capabilities for oral and topical medications. This milestone extends LifeMD’s pharmacy growth strategy by enabling its vertically integrated platform to deliver tailored therapies designed to meet evolving patient needs while improving efficiency and reducing reliance on third-party providers.
LifeMD’s commercial pharmacy, launched in August 2024 with capacity to process up to 5,000 prescriptions per day, can now formulate customized medications, including allergen-free and combination products not commercially available. These capabilities align with LifeMD’s core service areas in men’s and women’s health, dermatology, and beyond. The addition strengthens the Company’s ability to support specialized therapies while driving operational savings, shortening fulfillment times, and improving patient convenience.
“Every action we take is focused on strengthening LifeMD’s ability to deliver higher-quality, more accessible care to our patients,” said Justin Schreiber, Chairman and CEO of LifeMD. “By expanding our pharmacy with non-sterile compounding, we are not just adding capabilities, we’re building toward a future where every patient’s care is seamless, personalized, and accessible. This advancement complements our core service areas and brings us closer to delivering an unmatched healthcare experience, where convenience, continuity, and innovation come together to provide the kind of care that people want and deserve.”
LifeMD’s compounding pharmacy operates under the U.S. Food and Drug Administration’s 503A designation to directly meet specific patient needs with custom-formulated products. The Company is committed to adhering to strict quality and safety standards set by both federal and state regulations. LifeMD’s pharmacy is currently licensed in 13 states, with expectations to attain licenses in all 50 states within the next 12 months.
About LifeMD, Inc.
LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men’s and women’s health, weight management, and hormone therapy. The Company leverages a vertically integrated, proprietary digital care platform, a 50-state affiliated medical group, a state-of-the-art affiliated compounding pharmacy, and a U.S.-based patient care center to increase access to high-quality and affordable care. For more information, please visit LifeMD.com.
Cautionary Note Regarding Forward Looking Statements
This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section 21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this news release may be identified by the use of words such as: “believe,” “expect,” “anticipate,” “project,” “should,” “plan,” “will,” “may,” “intend,” “estimate,” “predict,” “continue,” and “potential,” or, in each case, their negative or other variations or comparable terminology referencing future periods. Examples of forward-looking statements include, but are not limited to, statements regarding our financial outlook and guidance, short and long-term business performance and operations, future revenues and earnings, regulatory developments, legal events or outcomes, ability to comply with complex and evolving regulations, market conditions and trends, new or expanded products and offerings, growth strategies, underlying assumptions, and the effects of any of the foregoing on our future results of operations or financial condition.
Forward-looking statements are not historical facts and are not assurances of future performance. Rather, these statements are based on our current expectations, beliefs, and assumptions regarding future plans and strategies, projections, anticipated and unanticipated events and trends, the economy, and other future conditions, including the impact of any of the aforementioned on our future business. As forward-looking statements relate to the future, they are subject to inherent risk, uncertainties, and changes in circumstances and assumptions that are difficult to predict, including some of which are out of our control. Consequently, our actual results, performance, and financial condition may differ materially from those indicated in the forward-looking statements. These risks and uncertainties include, but are not limited to, “Risk Factors” identified in our filings with the Securities and Exchange Commission, including, but not limited to, our most recently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any amendments thereto. Even if our actual results, performance, or financial condition are consistent with forward-looking statements contained in such filings, they may not be indicative of our actual results, performance, or financial condition in subsequent periods.
Any forward-looking statement made in the news release is based on information currently available to us as of the date on which this release is made. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as may be required under applicable law or regulation.
Investor Contact:
Marc Benathen, Chief Financial Officer
marc@lifemd.com
Media Contact:
Jessica Friedeman, Chief Marketing and Product Officer
press@lifemd.com
FAQ
What new pharmacy capabilities did LifeMD (LFMD) announce in September 2025?
How many prescriptions can LifeMD's commercial pharmacy process daily?
In how many states is LifeMD's pharmacy currently licensed?
What type of FDA designation does LifeMD's compounding pharmacy operate under?
What are the main therapeutic areas served by LifeMD's expanded pharmacy services?
